Visceral fat is referred to as the fat stored on the abdominal cavity of the body, and it is also the most dangerous kind of fat we can have. But the good news is that it can be reduced or prevented with diet and exercise, and a new report reveals what to drink that can help.
Express reports that a certain drink can be good for helping reduce the visceral fat in the body. A study was conducted in Japan, on the link between vinegar and weight loss. The participants were asked to drink a beverage containing varying doses of vinegar - 750mg and 1500 mg or 0mg placebo - apple cider vinegar in particular, because it tasted better. The participants drank these drinks over a period of 12 weeks.
At the end of the 12 weeks, the researchers found that the participants who drank both kinds of apple cider vinegar doses experienced weight loss and reduced body fat percentage compared to those who only drank placebo.
Vinegar has always been used as a remedy for many health issues, and reducing visceral fat is one of them. Taking some vinegar or apple cider vinegar a day can not only reduce visceral fat, but it can lower the risks of conditions like hypertension, high blood pressure, even lowering triglyceride levels or bad cholesterol in the body.
Aside from apple cider vinegar, green tea has also been proven to help reduce visceral fat in the body. It is one of the healthiest drinks in the world and has always been known to help in weight loss, therefore, reducing visceral fat. This is because green tea is full of antioxidants as well as caffeine, a compound known to help burn fat.
There are many studies that back up this fact. One study about the catechins found in green tea revealed that while overall weight loss is substantial, most of it was visceral fat. While it may not seem much for those looking to drastically lose weight, green tea or apple cider vinegar still helps in weight loss, and best paired with a balanced diet and exercise.


Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 



